Advertisment

Senegal spends 40 billion CFA francs on Covid Vaccines

Discover how Senegal has invested nearly 40 billion CFA francs in COVID vaccines, prioritizing the vaccination of its citizens. Commercial agreements replaced donations, with some prices even surpassing those negotiated for Europe. Learn how the country spent $400,000 for 200,000 doses of Sinopharm, looking to kickstart its vaccination program. Additionally, find out how Senegal devotes 3.1 billion CFA francs annually to the Expanded Programme on Immunization. Exciting progress in manufacturing anti-COVID vaccines is also highlighted, including recent funding agreements with European nations, the World Bank, and the United States. With a factory set to launch by 2022, Senegal aims to reduce its reliance on vaccine imports.

author-image
Medriva Newsroom
New Update

NULL

Advertisment

Senegal has opened its cheque book to pay for the vaccination of its citizens against COVID.

Advertisment

Donations were swiftly replaced by commercial agreements, which often included prices that were far higher than those that had been provided to Europe.

For instance, Senegal, which wanted to begin its vaccination program as quickly as possible, spent $400,000 for 200,000 doses of Sinopharm, which was priced at $20 per unit.

Vaccines against the coronavirus were purchased by the state at a cost of almost 40 billion CFA francs between the years 2020 and 2021.

Advertisment

Abdou Karim Fofana, the minister whose responsibility it is to supervise the PSE and who has been appointed by the AS, has provided the information.

A total of 3.1 billion CFA francs are spent annually by Senegal as part of the Expanded Programme on Immunization to purchase vaccinations of different sorts.

It is important to take notice that we are making progress in Senegal toward the manufacturing of anti-Covid-19 vaccinations. On Friday, July 9, 2021, an agreement was made with many partners, including European nations, the World Bank, and the United States, for the funding of the first phase of the project.

A factory that is anticipated to begin production as early as 2022, while Africa now imports 99 percent of the vaccines it requires.

SN
Advertisment
Chat with Dr. Medriva !